Team Cymru today announced a new integration with The Vertex Project to bring Team Cymru's Pure Signal Data Ocean directly into Synapse Enterprise, Vertex's Central Intelligence System, designed to ...

Vertex Minerals (ASX:VTX) has connected the remote control unit in the Reward Gold Mine’s telehut to the Aramine underground ...

Vertex Pharmaceuticals presents clinical data demonstrating benefits of Casgevy in SCD and TDT patients aged 5+ at ASH ...

Singapore-based deeptech startup SynaXG has secured more than $20 million in its first funding round, backed by January ...

If you have ever wondered whether Vertex Pharmaceuticals is a bargain right now, you are not alone. Let's break down whether the current price really stacks up to the company's fundamentals. Despite ...

Vertex Pharmaceuticals recently presented updated interim data at the 2025 ASN Kidney Week, revealing significant proteinuria reductions and eGFR stabilization with povetacicept in patients with IgA ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported third-quarter net income of $1.08 billion. On a per-share basis, the Boston-based company said it had profit of $4.20.

There's more good news than bad news for this big biotech stock. Were Vertex's Q2 results horrible? Not at all. Instead, investors reacted negatively after the big biotech company announced two ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

Vertex Pharmaceuticals (NASDAQ:VRTX) shares fell in premarket trading on Tuesday after the company's VX-993 failed to meet the primary endpoint in the Phase 2 pain study, offsetting a strong quarterly ...

Aug 4 (Reuters) - Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of ...